ANDA 203904, held by Methodist Hosp Res. Fludeoxyglucose F-18.
As of Nov 16, 2026, ANDA 203904 (Fludeoxyglucose F18), held by Methodist Hosp Res, was first approved by FDA on Apr 23, 2015, with 0 approved supplements and 0 published complete response letters.
1. Indications and Usage Fludeoxyglucose F18 Injection USP is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F18 Injection USP is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 23, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fludeoxyglucose F1820-300mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters